• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians.

作者信息

Wang Bei, Goh Yun Shan, Fong Siew-Wai, Young Barnaby Edward, Ngoh Eve Zi Xian, Chavatte Jean-Marc, Salleh Siti Nazihah Mohd, Yeo Nicholas Kim-Wah, Amrun Siti Naqiah, Hor Pei Xiang, Loh Chiew Yee, Lee Chia Yin, Chan Yi-Hao, Chang Zi Wei, Tay Matthew Zirui, Rouers Angeline, Torres-Ruesta Anthony, Carissimo Guillaume, Soh Mun Kuen, Lee Raphael Tze Chuen, Xu Yani, Pada Surinder, Lin Raymond Tzer Pin, Leo Yee-Sin, Lye David C, Maurer-Stroh Sebastian, Ng Lisa F P, Renia Laurent, Wang Cheng-I

机构信息

Singapore Immunology Network, ASTAR, Singapore.

ASTAR Infectious Diseases Labs, A*STAR, Singapore.

出版信息

Lancet Reg Health West Pac. 2021 Oct;15:100276. doi: 10.1016/j.lanwpc.2021.100276. Epub 2021 Sep 20.

DOI:10.1016/j.lanwpc.2021.100276
PMID:34568853
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8450274/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7d/8456057/85c0087b494f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7d/8456057/75a739a713f3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7d/8456057/85c0087b494f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7d/8456057/75a739a713f3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf7d/8456057/85c0087b494f/gr2.jpg

相似文献

1
Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）Delta变异株对亚洲人接种BNT162b2疫苗后产生的抗体中和作用的抗性
Lancet Reg Health West Pac. 2021 Oct;15:100276. doi: 10.1016/j.lanwpc.2021.100276. Epub 2021 Sep 20.
2
Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.BNT162b2疫苗诱导产生的针对真实B.1、B.1.1.7、B.1.351、B.1.525和P.1型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的中和抗体血清学调查
Emerg Microbes Infect. 2021 Dec;10(1):1241-1243. doi: 10.1080/22221751.2021.1940305.
3
The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）D614G突变对BNT162b2疫苗诱导的中和作用。
NPJ Vaccines. 2021 Mar 25;6(1):44. doi: 10.1038/s41541-021-00313-8.
4
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
5
Characterization of a new SARS-CoV-2 variant that emerged in Brazil.巴西出现的一种新型 SARS-CoV-2 变体的特征。
Proc Natl Acad Sci U S A. 2021 Jul 6;118(27). doi: 10.1073/pnas.2106535118.
6
Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual.严重急性呼吸综合征冠状病毒2型阿尔法变异株（B.1.1.7）在接种BNT162b2疫苗个体中的传播
Open Forum Infect Dis. 2021 Jul 20;8(8):ofab369. doi: 10.1093/ofid/ofab369. eCollection 2021 Aug.
7
BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.编码严重急性呼吸综合征冠状病毒2（SARS-CoV-2）P2 S的BNT162b2疫苗可保护转基因人血管紧张素转换酶2（hACE2）小鼠免受2019冠状病毒病（COVID-19）感染。
Vaccines (Basel). 2021 Apr 1;9(4):324. doi: 10.3390/vaccines9040324.
8
Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis.接受血液透析患者接种 1 剂 BNT162b2 疫苗后的短期抗体反应。
CMAJ. 2021 May 31;193(22):E793-E800. doi: 10.1503/cmaj.210673. Epub 2021 May 12.

引用本文的文献

1
Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis.接受维持性血液透析的患者对两剂ChAdOx1 nCoV-19疫苗接种的体液免疫反应轨迹
Microbiol Spectr. 2023 Feb 21;11(2):e0344522. doi: 10.1128/spectrum.03445-22.
2
Six-month longitudinal immune kinetics after mRNA-1273 vaccination: Correlation of peak antibody response with long-term, cross-reactive immunity.mRNA-1273 疫苗接种后 6 个月的纵向免疫动力学：峰值抗体反应与长期交叉反应性免疫的相关性。
Front Immunol. 2023 Jan 9;13:1035441. doi: 10.3389/fimmu.2022.1035441. eCollection 2022.
3
Characterization of two linear epitopes SARS CoV-2 spike protein formulated in tandem repeat.

本文引用的文献

1
Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta).关注的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）变异株的临床和病毒学特征：比较 B.1.1.7（阿尔法）、B.1.351（贝塔）和 B.1.617.2（德尔塔）的回顾性队列研究。
Clin Infect Dis. 2022 Aug 24;75(1):e1128-e1136. doi: 10.1093/cid/ciab721.
2
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.疫苗和恢复期血清对 SARS-CoV-2 B.1.617 中和能力降低。
Cell. 2021 Aug 5;184(16):4220-4236.e13. doi: 10.1016/j.cell.2021.06.020. Epub 2021 Jun 17.
3
串联重复构建的 SARS-CoV-2 刺突蛋白两个线性表位的特征。
PLoS One. 2023 Jan 20;18(1):e0280627. doi: 10.1371/journal.pone.0280627. eCollection 2023.
4
Does the COVID-19 XBB Omicron subvariant signal the beginning of the end of the pandemic?新冠病毒XBB奥密克戎亚变体是否预示着大流行结束的开始？
Singapore Med J. 2024 Dec 1;65(12):658-664. doi: 10.4103/singaporemedj.SMJ-2022-180. Epub 2022 Dec 1.
5
Wastewater surveillance of SARS-CoV-2 and chemical markers in campus dormitories in an evolving COVID - 19 pandemic.新冠病毒在不断演变大流行期间对 SARS-CoV-2 和校园宿舍化学标记物的污水监测
J Hazard Mater. 2023 Mar 15;446:130690. doi: 10.1016/j.jhazmat.2022.130690. Epub 2022 Dec 28.
6
Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia.在哥伦比亚新冠疫情的四个流行高峰期间，灭活全病毒疫苗和基因疫苗引发的针对主要新冠病毒变异株的中和抗体反应
Vaccines (Basel). 2022 Dec 14;10(12):2144. doi: 10.3390/vaccines10122144.
7
Conserved longitudinal alterations of anti-S-protein IgG subclasses in disease progression in initial ancestral Wuhan and vaccine breakthrough Delta infections.在最初的武汉原始毒株感染和疫苗突破性德尔塔毒株感染的疾病进展过程中，抗S蛋白IgG亚类的保守纵向变化。
Front Microbiol. 2022 Nov 22;13:1043049. doi: 10.3389/fmicb.2022.1043049. eCollection 2022.
8
Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals.接种 BNT162b2 疫苗加强针 5 个月后老年人对 Delta 和奥密克戎变异株特异性抗体滴度的下降
Front Immunol. 2022 Nov 14;13:1031852. doi: 10.3389/fimmu.2022.1031852. eCollection 2022.
9
Immunization with a Prefusion SARS-CoV-2 Spike Protein Vaccine (RBMRNA-176) Protects against Viral Challenge in Mice and Nonhuman Primates.用预融合SARS-CoV-2刺突蛋白疫苗（RBMRNA-176）免疫可保护小鼠和非人灵长类动物免受病毒攻击。
Vaccines (Basel). 2022 Oct 11;10(10):1698. doi: 10.3390/vaccines10101698.
10
Boosting the detection performance of severe acute respiratory syndrome coronavirus 2 test through a sensitive optical biosensor with new superior antibody.通过具有新型优质抗体的灵敏光学生物传感器提高严重急性呼吸综合征冠状病毒2检测性能。
Bioeng Transl Med. 2022 Sep 16;8(5):e10410. doi: 10.1002/btm2.10410.
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.
SARS-CoV-2 mRNA 疫苗接种诱导针对 NTD、RBD 和 S2 的具有不同功能的抗体。
Cell. 2021 Jul 22;184(15):3936-3948.e10. doi: 10.1016/j.cell.2021.06.005. Epub 2021 Jun 8.
4
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.BNT162b2疫苗对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株B.1.617.2和B.1.351的中和抗体活性
Lancet. 2021 Jun 19;397(10292):2331-2333. doi: 10.1016/S0140-6736(21)01290-3. Epub 2021 Jun 3.
5
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.SARS-CoV-2 变异株 P.1 对抗体中和的抵抗力增强。
Cell Host Microbe. 2021 May 12;29(5):747-751.e4. doi: 10.1016/j.chom.2021.04.007. Epub 2021 Apr 18.
6
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
7
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.SARS-CoV-2 变异株对单克隆和血清来源的多克隆抗体中和作用的抗性。
Nat Med. 2021 Apr;27(4):717-726. doi: 10.1038/s41591-021-01294-w. Epub 2021 Mar 4.
8
Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic individuals with COVID-19.COVID-19 无症状和有症状个体中总抗刺突抗体和同种型转换的敏感检测。
Cell Rep Med. 2021 Feb 16;2(2):100193. doi: 10.1016/j.xcrm.2021.100193. Epub 2021 Jan 16.
9
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
10
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction.一种基于抗体介导的 ACE2-刺突蛋白-蛋白相互作用阻断的 SARS-CoV-2 假病毒中和试验。
Nat Biotechnol. 2020 Sep;38(9):1073-1078. doi: 10.1038/s41587-020-0631-z. Epub 2020 Jul 23.